替非珠單抗

化合物

替非珠單抗INN:Tefibazumab)是一種人源化單株抗體,用於治療金黃色葡萄球菌的嚴重感染。可能的適應症包括治療患有囊性纖維化的2a期患者的金黃色葡萄球菌[1]耐甲氧西林金黃色葡萄球菌[2]該藥物由Inhibitex開發的。[3]

替非珠單抗
單株抗體
種類完整抗體
目標聚集因子A英語Clumping factor A
臨床資料
商品名英語Drug nomenclatureAurexis
其他名稱特非珠單抗、INH-H 2002
ATC碼
  • 未分配
識別資訊
CAS號521079-87-8  ☒N
ChemSpider
UNII
KEGG
化學資訊
化學式C6548H10122N1730O2034S44
摩爾質量147,035.72 g·mol−1

參見

參考資料

  1. ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
  2. ^ Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Patents on Anti-Infective Drug Discovery. January 2008, 3 (1): 10–33. PMID 18221183. doi:10.2174/157489108783413173. 
  3. ^ John JF. Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection. Current Opinion in Molecular Therapeutics. October 2006, 8 (5): 455–60. PMID 17078388.